Cargando…
Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
Autores principales: | Gorini, Stefania, De Angelis, Antonella, Berrino, Liberato, Malara, Natalia, Rosano, Giuseppe, Ferraro, Elisabetta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617926/ https://www.ncbi.nlm.nih.gov/pubmed/31346363 http://dx.doi.org/10.1155/2019/9601435 |
Ejemplares similares
-
Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
por: Gorini, Stefania, et al.
Publicado: (2018) -
Targeted Delivery of Doxorubicin Utilizing Chitosan Nanoparticles Surface Functionalized with Anti Her2 Trastuzumab [Corrigendum]
Publicado: (2022) -
Corrigendum to “Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer”
por: Yang, Guangda, et al.
Publicado: (2020) -
Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
Publicado: (2019) -
Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC [Corrigendum]
Publicado: (2021)